AstraZeneca plc (AZN) Earns Buy Rating from Citigroup Inc.
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by equities researchers at Citigroup Inc. in a report released on Wednesday. They presently have a GBX 6,000 ($78.32) target price on the biopharmaceutical company’s stock. Citigroup Inc.’s price objective points to a potential upside of 17.97% from the company’s current price.
Several other equities research analysts have also recently weighed in on AZN. Bryan, Garnier & Co reissued a “buy” rating on shares of AstraZeneca plc in a research report on Thursday, July 28th. Morgan Stanley reissued an “overweight” rating and issued a GBX 5,000 ($65.27) price objective on shares of AstraZeneca plc in a research report on Monday, July 11th. Credit Suisse Group AG reissued an “underperform” rating and issued a GBX 4,000 ($52.21) price objective on shares of AstraZeneca plc in a research report on Monday, June 27th. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price objective on AstraZeneca plc and gave the company a “sell” rating in a research report on Tuesday. Finally, Jefferies Group increased their price objective on AstraZeneca plc from GBX 4,100 ($53.52) to GBX 4,450 ($58.09) and gave the company a “hold” rating in a research report on Thursday, June 30th. Five research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of GBX 4,937.91 ($64.46).
Shares of AstraZeneca plc (LON:AZN) traded up 1.19% during trading on Wednesday, hitting GBX 5086.00. 3,384,720 shares of the stock traded hands. The firm’s 50-day moving average price is GBX 5,005.11 and its 200-day moving average price is GBX 4,435.88. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The company’s market cap is GBX 64.34 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/08/astrazeneca-plc-azn-earns-buy-rating-from-citigroup-inc-2.html
The company also recently announced a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were given a GBX 68.70 ($0.90) dividend. This represents a yield of 1.37%. The ex-dividend date was Thursday, August 11th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.